Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Portola Pharmaceuticals, which discovers and develops therapeutics for cardiovascular and autoimmune/inflammatory diseases, has started a Phase 1 trial with PRT062607 in healthy volunteers.
Subscribe to our email newsletter
PRT062607 is a novel, oral Spleen Tyrosine Kinase (Syk)-specific kinase inhibitor in development to treat chronic inflammatory diseases, including rheumatoid arthritis and systemic lupus erythematosis, and certain cancers, including non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.
The Phase 1 multiple ascending dose trial expects to evaluate the safety, pharmacokinetics and pharmcodynamics of oral PRT062607 in 40 healthy individuals.
The trial is expected to be completed in mid-2011.
Portola Pharma Research & Development executive vice president John Curnutte said the goal of Syk-JAK franchise is to develop safe and efficacious oral drugs for rheumatoid arthritis and other chronic inflammatory diseases and oncology indications.
"The Phase 1 multiple ascending dose study of our oral Syk-specific inhibitor will help us understand the appropriate dose range to explore in patients," Curnutte said.